PFO
INFI

Pathstone Family Office’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Pathstone Family Office’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,619
Closed -$17K – 637
2016
Q4 		$17K Buy
+12,619
New +$16.5K 0.01% 96

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Pathstone Family Office's INFI Position: Q1 2017 in Review

Pathstone Family Office sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2017, closing a stake of 12,619 shares — an estimated $17K sold.

Pathstone Family Office first reported a position in INFI in Q4 2016 and held it in 1 quarter. The position peaked at $17K in Q4 2016. 80 funds tracked by Wall St. Rank hold INFI as of Q1 2017.

  • Pathstone Family Office reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Pathstone Family Office sold 12,619 Infinity Pharmaceuticals, Inc. shares in Q1 2017, an estimated $17K.
  • Pathstone Family Office first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Pathstone Family Office's Infinity Pharmaceuticals, Inc. position peaked at $17K in Q4 2016.
  • 80 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2017.

Based on Pathstone Family Office's 13F filing for Q1 2017, filed 12 May 2017.